NCT01143545: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas |
|
|
| Terminated | 1 | 10 | US | Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide | National Cancer Institute (NCI) | Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma | 02/15 | 02/20 | | |
NCT01313429: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum |
|
|
| Terminated | 1 | 19 | US | Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib | National Cancer Institute (NCI) | Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies | 02/20 | 02/20 | | |
